Hamelin A, Amsler E, Mathelier-Fusade P, Pecquet C, Bayrou O, Barbaud A, Soria A
Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.
Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.
Ann Dermatol Venereol. 2019 Jan;146(1):9-18. doi: 10.1016/j.annder.2018.07.031. Epub 2019 Jan 9.
Assessment of the efficacy and safety of omalizumab in chronic urticaria refractory to conventional treatment (H1-antihistamines at high dosage and montelukast) in real-life practice.
A retrospective, descriptive, single-centre study was performed of the data for all patients presenting refractory chronic spontaneous urticaria or inducible urticaria and receiving omalizumab (300mg every four weeks) from November 2012 to June 2016.
In all, 23 patients were included. Omalizumab led to complete or significant remission in 19 patients (83%) with chronic urticaria, with remission in 9 patients (47%) occurring within 72hours of the first injection. One patient had a partial response and 3 (13%) showed no response. Only 2 patients (9%) in complete remission stopped their treatment at 1 and 3 years. 52% of patients presented non-serious adverse events, which in one case resulted in treatment withdrawal.
Omalizumab exhibited good real-life efficacy in a small series of chronic urticaria patients in France.
评估在实际临床中，奥马珠单抗对常规治疗（高剂量H1抗组胺药和孟鲁司特）无效的慢性荨麻疹的疗效和安全性。
进行了一项回顾性、描述性、单中心研究，纳入2012年11月至2016年6月间所有患有难治性慢性自发性荨麻疹或诱导性荨麻疹且接受奥马珠单抗治疗（每四周300mg）的患者的数据。
共纳入23例患者。奥马珠单抗使19例（83%）慢性荨麻疹患者实现完全或显著缓解，其中9例（47%）在首次注射后72小时内缓解。1例患者部分有效，3例（13%）无反应。仅2例完全缓解患者在1年和3年时停药。52%的患者出现非严重不良事件，其中1例导致停药。
在法国的一小部分慢性荨麻疹患者中，奥马珠单抗显示出良好的实际疗效。
